Tianyan Chen and Norah Terrault
INTRODUCTION
Chronic hepatitis C virus (HCV) infection affects at least 170 million persons worldwide [1] and at least 3.5 million Americans are living with chronic hepatitis C [2] . In the United States, the highest prevalence of chronic hepatitis C is among those born between 1945 and 1965 (baby boomers) and more than 25% of these adults are estimated to have cirrhosis [3] . If untreated, those with cirrhosis have a risk of 3-5% per year of progressing to liver decompensation and 1-5% risk of developing hepatocellular carcinoma (HCC) [4] . Indeed, infection with chronic HCV remains the most common indication for liver transplantation in many countries, including the United States [5] . Thus, identifying those with HCV and cirrhosis is a high priority to provide access to curative therapy and reduce the HCV-associated morbidity and mortality.
Historically, treatment of HCV in patients with cirrhosis was characterized by low efficacy and poor tolerability, especially among those with hepatic decompensation. With the advent of safe and highly effective direct-acting antivirals (DAA) ( Table 1) , HCV eradication is achievable in the majority of patients providing an unprecedented opportunity to change the natural history of cirrhosis and prevent liver-related complications. However, the presence and severity of cirrhosis influence the likelihood of achieving sustained viral clearance and Child-Pugh class determines treatment options. For those patients with Child-Pugh B or C cirrhosis, use of protease inhibitors is not recommended [6] .
Potential treatment benefits among patients with cirrhosis include a reduced risk of progression to decompensation, HCC and liver-related death. In patients with decompensated cirrhosis, the ability to reverse symptoms of decompensation, improve quality of life and obviate the need for liver transplantation are additional potential benefits.
DIRECT-ACTING ANTIVIRALS IN HEPATITIS C VIRUS-INFECTED PATIENTS WITH COMPENSATED CIRRHOSIS

Goals of therapy
The achievement of sustained virological response (SVR) in individuals with cirrhosis has been shown to arrest fibrosis progression and even achieve fibrosis regression in some [7] [8] [9] [10] . Additional long-term benefits include reduced rates of hepatic decompensation, HCC development and liverrelated mortality [11, 12] .
Treatment options
The all-oral DAA-based regimens that are approved and anticipated in 2016 for genotypes 1 to 6 for individuals with compensated cirrhosis are shown in Table 2 . Generally, the SVR rates achieved in compensated cirrhosis are at least 90% for most combinations. To achieve optimal SVR rates, DAA regimens in patients with compensated cirrhosis frequently require the addition of ribavirin (RBV) and/or extension of the duration of treatment. The specific DAA therapy used to treat patients with compensated cirrhosis is guided by factors such as HCV genotype, previous treatment experience, renal function, drug-drug interactions and the severity of cirrhosis.
Safety of direct-acting antivirals in cirrhotics DAA-based therapies for patients with compensated cirrhosis are generally well tolerated. The majority of the serious adverse events were related to RBV dosing, including hemolytic anemia and renal dysfunction [6] . The risk of adverse events with 
KEY POINTS
Approved and soon-to-be approved all-oral DAA-based therapies have been shown to be highly effective and well tolerated in individuals with compensated and decompensated cirrhosis.
Viral eradication in compensated cirrhosis halts fibrosis progression and can result in fibrosis regression in some cases.
Longer-term benefits of successful HCV treatments in decompensated cirrhosis include improvements in liver disease severity and less frequent hepatic decompensation, which in turn prevent liver-related mortality and avoid the need for liver transplantation.
Optimal SVR rates typically necessitate prolonged treatment duration and/or the addition of RBV.
Treatment decisions are guided by HCV genotype, renal function, drug-drug interactions and the severity of cirrhosis.
Safety concerns are paramount in individuals with advanced liver disease and continued vigilance for hepatotoxicity and other complications is warranted, especially in those with decompensated cirrhosis.
RBV is dose-dependent, more frequent with more than 1000 mg daily dosing. For those with renal dysfunction, sofosbuvir (SOF)-based therapy is not recommended if the estimated glomerular filtration rate is less than 30 ml/min, because of the higher (up to 20-fold) exposures of the predominant SOF metabolite GS-331007 [13]. Ledipasvir (LDV) requires an acid environment for optimal absorption. The bioavailability of protease inhibitors can also be reduced with coadministration of proton pump inhibitors [14] . Lower drug levels are especially problematic with nonstructural protein 5A (NS5A) inhibitors because of the concern of preferentially selecting resistantassociated variants (RAVs) [15 & ]. Although bioavailability of protease inhibitors can be reduced at a higher gastric pH, their exposure level can be paradoxically increased when ritonavir is added in the combination. Consequently, use of high-dose proton pump inhibitors is discouraged with ombitasvir/ paritaprevir/ritonavir (OBV/PTVr) or LDV/SOF [15 & ,16] .
Genotype 1 Simeprevir (SMV) and SOF with or without RBV for 12-24 weeks is highly efficacious in treatment-nave and experienced individuals, as shown in both clinical trial and real-life settings [17, 18] . Relapse is more frequent in patients with genotype 1a with the Q80K polymorphism so baseline testing is recommended [6] . For treatment with LDV/SOF for 12 weeks, no RBV is recommended in treatment-nave patients but in treatment-experienced patients, either RBV should be added if treating for 12 weeks [19, 20] or the therapy extended to 24 weeks. For the combination of PTVr/OBV and dasabuvir (DSB), individuals with genotype 1b and Child-Pugh-A cirrhosis can be treated 12 weeks without RBV but those with genotype 1a require RBV and 24 weeks' treatment to achieve optimal SVR12 rates [21, 22] . Daclatasvir (DCV)/SOF with or without RBV for 24 weeks can be considered but has not been Food and Drug Administration (FDA)approved for genotype 1 [23] [24] [25] . Elbasvir/grazoprevir (EBR/GZP) without RBV for 12 weeks is an option for cirrhotics with genotype 1b and those with genotype 1a without high-fold baseline RAVs (at amino acid positions 28, 30, 31, or 93) [26, 27] .
Patients with genotype 1a with high-fold baseline NS5A RAVs treated with EBR/GRZ require the addition of RBV and extension of treatment to 16 weeks. Finally, the DAA combination of SOF/ velpatasvir (VEL), with anticipated approval in 2016, can be used for 12 weeks without RBV [28] .
Genotype 2
For genotype 2, SOF plus RBV for 16-24 weeks yields SVR12 rates varying from 73 to 84% in cirrhotics [23, 29] . For RBV ineligible patients, American Association for the Study of Liver Diseases-Infectious Diseases Society of America (AASLD-IDSA) guidance recommends treatment with DCV plus SOF for 16-24 weeks [23] . For SOF plus RBV failures, treatment with peg-interferon (IFN)/RBV and SOF for 12 weeks or DCV plus SOF with or without RBV for 24 weeks is recommended [6] . Looking to the near future, 12 weeks of SOF/VEL achieved an SVR12 rate of 100% and will be another RBV-free option [24, 28] .
Genotype 3
For genotype 3 patients with compensated cirrhosis, the addition of RBV seems to be important to improve SVR12 rates with most regimens. The preferred therapy is DCV/SOF with RBV for 16-24 weeks [30, 31] . Peg-IFN/RBV plus SOF for 12 weeks can be considered if the patient is IFN eligible [32] . The only RBV-free option recommended is EBR/GZP plus SOF for 12 weeks with SVR12 achieved in 91% of treatment-nave patients. SOF/VEL also achieved an SVR of 91% without use of RBV, suggesting this combination would be another RBV-free 12-week alternative when approved [33] . 
SPECIAL SUBGROUPS
Individuals with chronic kidney disease stage 4 or 5 (creatinine clearance < -30 ml/min) Nucleotide analogues such as SOF are primarily eliminated renally. Renal toxicities, including renal tubular injuries occur in a dose-dependent fashion. Therefore, use of SOF in patients with creatinine clearance (CrCl) less than 30 ml/min is not recommended. In the HCV-TARGET cohort, patients with a CrCl less than 30 ml/min who received SOF had similar SVR rates to those with normal renal function, but anemia and acute kidney injury were more frequently observed [35] , but some small case series (n ¼ 13 patients) suggested SOF at the dose of 400 mg daily was well tolerated [36, 37] . Pharmacokinetics studies are underway.
As SOF is the backbone in most currently approved DAA-based combinations, individuals with CKD stages 4 and 5 have more limited therapeutic options. Protease inhibitors or NS5A inhibitors combinations can be safely used in this situation. The RUBY-1 trial examined the safety of OBV/PTVr and DSB with or without RBV combination for 12 weeks in subjects with CKD stage 4 or 5. All four patients with genotype 1 and F3 disease achieved SVR12 [38] . In the C-SURFER trial using the EBZ/GZP combination for genotype 1 and CKD stage 4 or 5, six out of seven patients with compensated cirrhosis reached SVR12 [39] . These two treatment regimens are the mainstays of treating those with severe renal impairment but are only applicable to patients with compensated cirrhosis [6] . For patients with severe renal dysfunction and hepatic decompensation, there are no well tolerated treatment options available.
DIRECT-ACTING ANTIVIRALS IN HEPATITIS C VIRUS-INFECTED PATIENTS WITH DECOMPENSATED CIRRHOSIS
Goals of therapy
For patients who are not transplant candidates, the immediate goals of therapy are to reverse complications related to decompensation, improve biochemical indices of liver synthetic function and most importantly, to prevent liver-related deaths. With the availability of IFN-free therapy, these goals are realistic and early results point to the successes in achieving such improvements [40, 41] . For patients who are on the waiting list for liver transplantation, HCV therapy can also yield improvements in model for end-stage liver disease (MELD) and Child-Pugh scores, reverse or prevent worsening of liver decompensation and prevent wait-list mortality. For patients with HCC as a complication of cirrhosis, an additional benefit of HCV treatment is to aid in making patients suitable candidates for local regional therapy or systemic therapies. Whether successful HCV therapy can reduce the risk of HCC among those with decompensated cirrhosis is not yet known.
Although these benefits imply that treatment of all patients with decompensated cirrhosis should be undertaken, there are added complexities to this decision in the context of liver transplantation. For those on the waiting list, the reduction in MELD scores that accompany successful treatment in most patients may result in the patient landing in 'MELD purgatory' meaning the improved MELD is not enough to obviate the need for liver transplantation, but makes access to a transplant more difficult (Fig. 1) . Thus, the pros and cons of antiviral therapy among wait-listed patients ( Table 3 ) warrant careful consideration of the goals of therapy.
Treatment options
In contrast to patients with compensated cirrhosis, treatment options for those with decompensated cirrhosis are limited to NS5A and NS5B inhibitors (Table 1) . This is primarily related to safety concerns with use of protease inhibitors. The AASLD-IDSA HCV guidance specifically recommends against use of protease inhibitor-inclusive regimens in patients with decompensated cirrhosis [6] . This recommendation is conservative and, in part, likely reflects the availability of alternative drug combinations.
Currently recommended DAA therapies include SOF plus LDV or DCV with RBV for genotype 1, 3, 4, and 6 ( Table 4 ). For genotype 2, SOF plus RBV is recommended unless the patient is RBV ineligible; then SOF plus DCV is recommended. Child-Pugh class is a key predictor of SVR, with lower rates of sustained viral clearance achieved in those with Child-Pugh-B/C cirrhosis compared with Child-Pugh-A cirrhosis. Although SVR rates also appear lower in Child-Pugh-C compared with Child-Pugh-B cirrhotics, the total number of Child-Pugh-C patients treated in clinical trials is low and the competing risk of liver-related mortality from progressive, decompensated cirrhosis may contribute to lower SVR rates.
Safety considerations
As highlighted, protease inhibitors, as a class, are to be avoided because of risk of increased protease inhibitor levels in the setting of decompensated cirrhosis and concern for higher rates of adverse effects. The FDA recently added a black box warning to use of OBV/PTVr in individuals with decompensated cirrhosis, because of safety concerns [42], though no published data regarding the cases of decompensation OBV/PTVr plus DSB are available. In the clinical trial of PTVr/OBV and DSB with RBV in patients with Child-Pugh-B cirrhosis, hyperbilirubinema, and anemia were observed but there was no evidence of hepatotoxicity [43] . There is more extensive clinical experience with other protease inhibitors, specifically SMV, in patients with Child-Pugh-B cirrhosis. As this was the first all-oral ], highlighting the challenge in differentiating liver complications that are treatment related vs. those that reflect the natural history of HCV disease. In the IMPACT study of SOF/SMV/DCV, SMV exposures were shown to be 2.2-fold higher in Child-Pugh-B vs. Child-Pugh-A patients but with no evidence of hepatotoxicity or decompensating events, though one-third experienced hyperbilirubinemia [47] . EBR/GZP, recently approved for genotype 1, is not approved for patients with decompensated cirrhosis, and the only study in Child-Pugh-B patients utilized a 50 mg dose of GZP (vs. the 100 mg dose in the fixed-dose combination tablet approved).
Most regimens include RBV ( Table 4 ). The optimal RBV dose has not been formally studied. In many trials, the starting dose of RBV was 600-800 mg daily and was adjusted to tolerability. Treatment-related serious adverse effects attributed to RBV are frequent, especially anemia [48] . Recently, lactic acidosis was reported in a cohort of 32 patients with decompensated cirrhosis treated with nonprotease inhibitor-based therapy. Although this was attributed to mitochondrial toxicity possibly related to RBV and/or SOF, there was no evidence of hepatotoxicity [49 & ]. Again, the issue of whether this represents hepatotoxicity or the natural history of decompensated cirrhosis is difficult to discern [50] . These studies point to the importance of close monitoring during treatment as well as the need for more controlled studies [51] . Table 4 . Antiviral options for patients with chronic hepatitis C and decompensated cirrhosis (Fig. 2) . For those RBV ineligible, longer duration therapy is needed. LDV/SOF for 24 weeks achieves SVR12 in 94 and 82% in Child-Pugh-B and Child-Pugh-C patients [40, 52 & ], respectively. Looking to the next generation of NS5A inhibitors, the SOF/VEL combination in decompensated cirrhosis showed SVR12 rates of 88% with SOF/VEL for 12 weeks, 96% if RBV added, and 92% if treatment extended to 24 weeks [53 && ]. Collectively, these results support use of RBV in all regimens to enhance SVR rates but in those patients who are truly RBV ineligible, extension of treatment to 24 weeks is the next best alternative. As highlighted above, SMV/SOF is not recommended by the AASLD-IDSA guidance for treatment of decompensated cirrhosis, though there is FDA approval for use in Child-Pugh-B and the considerable real-world experience supports its safety. However, SVR rates are only $75% overall, though at least 90% in genotype 1b [54] . Thus, for those rare circumstances where a protease inhibitor-inclusive regimen is essential (e.g., NS5A resistance), SMV/ SOF may be considered in patients with Child-Pugh-B cirrhosis.
Genotype 2
For patients able to tolerate RBV, DCV, SOF plus RBV for 24 weeks is recommended [6] and for patients with decompensated cirrhosis who are RBV ineligible, DCV plus SOF for 24 weeks can be considered, though the SVR rate is uncertain. Available numbers of patients with decompensated cirrhosis treated with DCV/SOF with and without RBV are very small (n ¼ 4-6 per study with SVR12 rates varying from 75-100%) [41, 55] . With the anticipated approval of SOF/VEL, this combination will be another RBV-free option for genotype 2, with 8/8 achieving SVR12 [53 && ]. Although SOF plus RBV can be considered as an alternative in patients with decompensated cirrhosis, the optimal treatment duration is unknown and currently listed as 'up to 48 weeks', making this a less attractive option.
Genotype 3
The combination of DCV, SOF plus RBV for 24 weeks is recommended [6] Treatment of chronic hepatitis C in patients Chen and Terrault treated for 24 weeks with DCV plus SOF and RBV, and 4/5 achieved SVR [41] . A larger experience with decompensated cirrhosis comes from the compassionate access programs, where SVR rates vary from 67 to 100% (average 83%), with SVR rates improved by addition of RBV (12 weeks) and/or longer duration therapy (24 weeks) [56] , especially among patients with Child-Pugh-C cirrhosis [57 && ]. A total of 39 patients with genotype 3 were included in the SOF/VEL study of decompensated cirrhosis; the best SVR (85%) was achieved with SOF/VEL plus RBV for 12 weeks [53 && ]. Collectively, these studies suggest RBV is likely to remain an essential component of therapy for decompensated cirrhotics, especially if shorter duration therapy (12 weeks) is used. Additional drug combinations are needed for genotype 3 patients to further enhance SVR rates.
Genotype 4
For genotype 4 with decompensated cirrhosis, available DAA-based regimens are similar to those for genotype 1 [58] [59] [60] [61] [62] .
CONCLUSION
Remarkable advances have been made in the treatment of HCV in patients with compensated and decompensated cirrhosis. Although the majority of these patients can achieve virologic cure with current DAA options, this group remains more difficult to cure. Achievement of optimal SVR rates requires longer duration therapy and/or more complex combinations of drugs, including RBV. Whether at least 95% cure rates can be achieved with future triple or quad DAA combinations remains to be seen, but early studies are encouraging. Safety concerns remain paramount in those with advanced liver disease and continued vigilance for hepatotoxicity and other complications is warranted, especially in patients with decompensated cirrhosis. Finally, more long-term data are needed on the reversibility of cirrhosis and decompensation. Short-term results (up to 1 year) suggest the majority of patients will achieve some reductions in MELD and Child-Pugh scores with successful treatment [41,53 && ] but more data are needed regarding the frequency of reversing symptoms of decompensation, avoiding liver transplantation and preventing liver-related mortality, especially among those with decompensated cirrhosis. Understanding the pretreatment factors that predict clinical benefits vs. harm is of paramount importance.
